Jiangsu Hengrui Medicine Co., Ltd. Announcement on the Completion of Lock-up Period Unlocking for Employee Shareholding Plan

2026-04-08 06:05:42

Stock code: 600276 Stock abbreviation: Hengrui Medicine Announcement No.: Lin 2026-057

Jiangsu Hengrui Medicine Co., Ltd.

Announcement on the completion of the unlocking and release of shares under the employee share ownership plan lock-up period

This company’s board of directors and all directors, supervisors, and senior management of this company warrant that there are no false records, misleading statements, or material omissions in the contents of this announcement, and they assume legal responsibility for the authenticity, accuracy, and completeness of the contents.

Jiangsu Hengrui Medicine Co., Ltd. (hereinafter referred to as the “Company”) has completed the sale or transfer of all shares subject to the second lock-up period under the Company’s 2023 employee share ownership plan and the first lock-up period under the Company’s 2024 employee share ownership plan. The related matters are hereby announced as follows:

I. Implementation of the employee share ownership plan

(I) 2023 employee share ownership plan

On November 3, 2023, the Company held the 6th meeting of the 9th session of the board of directors and the 5th meeting of the 9th session of the board of supervisors, and on November 23, 2023, it convened the 2nd extraordinary general meeting of shareholders in 2023, at which the Company’s 2023 employee share ownership plan was considered and approved. For details, please refer to the relevant announcements disclosed by the Company on November 4, 2023 and November 24, 2023 on the Shanghai Stock Exchange website (www.sse.com.cn).
On December 27, 2023, the Company received the “Transfer Registration Confirmation Letter” issued by China Securities Depository and Clearing Co., Ltd. The 11.5 million shares of the Company held in the Company’s repurchase-dedicated securities account were transferred on December 26, 2023 to the securities account of the Company’s 2023 employee share ownership plan by non-trading transfer. The transfer price was RMB 23.85 per share. For details, please refer to the Company’s “Announcement on Completion of Non-trading Transfer under the 2023 Employee Share Ownership Plan of Hengrui Medicine” disclosed on December 28, 2023 on the Shanghai Stock Exchange website (www.sse.com.cn) (Announcement No.: Lin 2023-156).
On December 27, 2023, the Company held the first meeting of the holders under the 2023 employee share ownership plan, at which the “Proposal on Establishing the Management Committee for the 2023 Employee Share Ownership Plan of Jiangsu Hengrui Medicine Co., Ltd.” was considered and approved. The Company established the Management Committee for the 2023 employee share ownership plan (hereinafter referred to as the “Management Committee”), which is responsible for the daily supervision and management of the employee share ownership plan and represents the holders to exercise shareholder rights. The term of existence of the Management Committee is the same as the term of existence of the 2023 employee share ownership plan. For details, please refer to the Company’s “Resolution Announcement of the First Meeting of the Holders under the 2023 Employee Share Ownership Plan of Hengrui Medicine” disclosed on December 28, 2023 on the Shanghai Stock Exchange website (www.sse.com.cn) (Announcement No.: Lin 2023-157).
On March 31, 2025, the Company disclosed the “Promotional Announcement on the Satisfaction of Unlocking Conditions for Certain Tranches under the 2023 Employee Share Ownership Plan of Hengrui Medicine” (Announcement No.: Lin 2025-041). The partial tranches unlockable under the first lock-up period of the Company’s 2023 share ownership plan have met the unlocking conditions. A total of 1,050 holders that meet the unlocking conditions are involved, corresponding to 4.1605 million shares of stock rights and interests, accounting for 0.06% of the Company’s total share capital.
On April 9, 2025, the Company disclosed the “Announcement on the Completion of the Execution of Unlocking of Shares under the First Lock-up Period of the 2023 Employee Share Ownership Plan of Hengrui Medicine” (Announcement No.: Lin 2025-050). All of the shares released from the first lock-up period under the Company’s 2023 employee share ownership plan have been fully sold or transferred.
On March 26, 2026, the Company disclosed the “Promotional Announcement on the Satisfaction of Unlocking Conditions for Certain Tranches under the Employee Share Ownership Plan” (Announcement No.: Lin 2026-053). The partial tranches unlockable under the second lock-up period of the Company’s 2023 employee share ownership plan have met the unlocking conditions. A total of 949 holders that meet the unlocking conditions are involved, corresponding to 2.8153 million shares of stock rights and interests, accounting for 0.04% of the Company’s total share capital.

(II) 2024 employee share ownership plan

On August 20, 2024, the Company held the 10th meeting of the 9th session of the board of directors and the 7th meeting of the 9th session of the board of supervisors, and on September 6, 2024, convened the 1st extraordinary general meeting of shareholders in 2024, at which the Company’s 2024 employee share ownership plan was considered and approved. For details, please refer to the relevant announcements disclosed by the Company on August 22, 2024 and September 7, 2024 on the Shanghai Stock Exchange website (www.sse.com.cn).
On December 27, 2024, the Company received the “Transfer Registration Confirmation Letter” issued by China Securities Depository and Clearing Co., Ltd. The 12.2 million shares of the Company held in the Company’s repurchase-dedicated securities account were transferred on December 27, 2024 to the securities account of the Company’s 2024 employee share ownership plan by non-trading transfer. The transfer price was RMB 21.20 per share. For details, please refer to the Company’s “Announcement on Completion of Non-trading Transfer under the 2024 Employee Share Ownership Plan of Hengrui Medicine” disclosed on December 30, 2024 on the Shanghai Stock Exchange website (www.sse.com.cn) (Announcement No.: Lin 2024-161).
On December 27, 2024, the Company held the first meeting of the holders under the 2024 employee share ownership plan, at which the “Proposal on Establishing the Management Committee for the 2024 Employee Share Ownership Plan of Jiangsu Hengrui Medicine Co., Ltd.” was considered and approved. The Company established the Management Committee for the 2024 employee share ownership plan (hereinafter referred to as the “Management Committee”), which is responsible for the daily supervision and management of the employee share ownership plan and represents the holders to exercise shareholder rights. The term of existence of the Management Committee is the same as the term of existence of the 2024 employee share ownership plan. For details, please refer to the Company’s “Resolution Announcement of the First Meeting of the Holders under the 2024 Employee Share Ownership Plan of Hengrui Medicine” disclosed on December 30, 2024 on the Shanghai Stock Exchange website (www.sse.com.cn) (Announcement No.: Lin 2024-162).
On March 26, 2026, the Company disclosed the “Promotional Announcement on the Satisfaction of Unlocking Conditions for Certain Tranches under the Employee Share Ownership Plan” (Announcement No.: Lin 2026-053). The partial tranches unlockable under the first lock-up period of the Company’s 2024 employee share ownership plan have met the unlocking conditions. A total of 1,054 holders that meet the unlocking conditions are involved, corresponding to 4.2674 million shares of stock rights and interests, accounting for 0.06% of the Company’s total share capital.

II. Sale or transfer of shares released from the lock-up period under the employee share ownership plan

(I) 2023 employee share ownership plan

The Company’s 2023 employee share ownership plan’s second lock-up period actual shares released for unlocking totaled 2.8153 million shares (accounting for 0.04% of the Company’s total share capital as of now). As of the date of disclosure of this announcement, 1.7657 million shares were transferred to the holders of the employee share ownership plan by non-trading transfer, and 1.0495 million shares were sold through centralized competitive trading. The Management Committee of the Company’s 2023 employee share ownership plan will carry out the corresponding allocation of assets in accordance with the relevant provisions of this employee share ownership plan.

(II) 2024 employee share ownership plan

The Company’s 2024 employee share ownership plan’s first lock-up period actual shares released for unlocking totaled 4.2674 million shares (accounting for 0.06% of the Company’s total share capital as of now). As of the date of disclosure of this announcement, 2.4351 million shares were transferred to the holders of the employee share ownership plan by non-trading transfer, and 1.8323 million shares were sold through centralized competitive trading. The Management Committee of the Company’s 2024 employee share ownership plan will carry out the corresponding allocation of assets in accordance with the relevant provisions of this employee share ownership plan.

III. Other explanations

The Company will continue to monitor the implementation progress of this employee share ownership plan and, in accordance with the relevant laws and regulations, timely fulfill its information disclosure obligations. Investors are kindly requested to pay attention to the relevant announcements and be mindful of investment risks.

This is hereby announced.

Board of Directors of Jiangsu Hengrui Medicine Co., Ltd.

April 3, 2026

A wealth of information and precise interpretation—available on the Sina Finance app

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.